Recently, a phase II, open-label clinical trial examined for the first time the safety and efficacy of IL-18 blockade in patients with AOSD [82]: 23 refractory AOSD patients were recruited, presenting with fever or CRP levels greater than 10 mg/l. The gene discussed is IL18; the disease is adult-onset Still disease.